Business Context and Reporting Period
Company: Immunocore Holdings Plc
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Three and six months ended June 30, 2023
Filing Date: August 10, 2023
Context: This filing incorporates by reference the Unaudited Condensed Consolidated Interim Financial Statements, Management's Discussion and Analysis (MD&A), a Press Release, and an Earnings Conference Call Presentation. The registrant files annual reports under Form 20-F.
Key Financial Metrics
The provided text serves as a cover sheet and index for the Form 6-K filing. It references the financial data in Exhibits 99.1 and 99.2 but does not contain the specific numerical values within this document.
- Revenue: Not provided in this text (refer to Exhibit 99.1).
- Profit/Loss: Not provided in this text (refer to Exhibit 99.1).
- Cash Flow: Not provided in this text (refer to Exhibit 99.1).
- Margins: Not provided in this text (refer to Exhibit 99.1).
- Debt and Liquidity: Not provided in this text (refer to Exhibit 99.1).
Material Changes
The filing text does not provide specific comparative data or material changes versus the prior period. Investors must refer to the incorporated Exhibit 99.2 (MD&A) for a discussion of results of operations and financial condition changes.
Guidance, Outlook, and Risks
Forward-Looking Statements: The filing contains forward-looking statements based on the Company's expectations as of August 10, 2023. These include words such as "may," "will," "expect," and "plan."
Risks and Uncertainties: Actual results may differ materially from these statements due to risks and uncertainties. The filing directs readers to the "Risk Factors" and "Management's Discussion and Analysis" sections in the Company's SEC filings for a detailed discussion of these factors.
Update Obligation: The Company undertakes no obligation to publicly update forward-looking statements except as required by law.
Investor Verification Checklist
- Review Exhibit 99.1 for the specific Unaudited Condensed Consolidated Interim Financial Statements to verify revenue, net loss, and cash position.
- Consult Exhibit 99.2 for Management's Discussion and Analysis to understand the drivers of financial performance and material changes.
- Read Exhibit 99.3 (Press Release) and Exhibit 99.4 (Conference Call Presentation) for management commentary on clinical progress and strategic outlook.
- Verify the "Risk Factors" section in the most recent Form 20-F to assess potential impacts on the forward-looking statements included in this report.